MedTrace Logo

An Imaging Study in ER Negative Breast Cancer by Targeting αvβ6

NCT06978478 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2025-05-18

No results posted yet for this study

Summary

This is a multicentre, pilot study that aims to determine the feasibility of \[18F\]-FBA-A20FMDV2-PET CT scans to detect levels of αvβ6 in patients with ER-ve αvβ6-positive metastatic or locally advanced breast cancer. A combination of factors will be used to determine the feasibility of \[18F\]-FBA-A20FMDV2-PET CT imaging including visual adequacy of the PET CT image, adequate signal to noise ratio and the ability to evaluate the image differential between the metastatic lesion(s) and normal tissue.

Conditions

Interventions

PROCEDURE

Unlabelled PET CT Scan

\[18F\]-FDG-PET CT

PROCEDURE

Labelled PET CT Scan

\[18F\]-FBA-A20FMDV2 -PET CT

Sponsors & Collaborators

  • Queen Mary University of London

    lead OTHER

Principal Investigators

  • Peter Schmid · Queen Mary University of London

  • John Marshall · Queen Mary University of London

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-19
Primary Completion
2020-07-27
Completion
2020-07-27

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06978478 on ClinicalTrials.gov